Parkside Financial Bank & Trust raised its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,527 shares of the biopharmaceutical company’s stock after buying an additional 1,495 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Bristol-Myers Squibb were worth $889,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in BMY. Garrett Wealth Advisory Group LLC acquired a new position in shares of Bristol-Myers Squibb during the third quarter valued at about $26,000. Lenox Wealth Advisors LLC increased its holdings in Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the period. Financial Gravity Wealth Inc. increased its holdings in Bristol-Myers Squibb by 101.2% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 327 shares during the period. 1 North Wealth Services LLC acquired a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $41,000. Finally, Endurance Wealth Management Inc. increased its holdings in Bristol-Myers Squibb by 119.6% in the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 500 shares during the period. 80.40% of the stock is owned by institutional investors and hedge funds.
In other news, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP John E. Elicker sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.
Shares of NYSE BMY traded up $0.44 during midday trading on Friday, reaching $58.02. 11,418,626 shares of the stock were exchanged, compared to its average volume of 12,766,524. The firm has a market cap of $91.88 billion, a price-to-earnings ratio of 14.58, a PEG ratio of 1.31 and a beta of 0.71. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $58.46. The firm has a 50-day simple moving average of $52.90 and a two-hundred day simple moving average of $48.19. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The business had revenue of $6.01 billion for the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $1.09 EPS. Research analysts expect that Bristol-Myers Squibb Co will post 4.33 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.41 per share. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 2.83%. Bristol-Myers Squibb’s payout ratio is 41.21%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: Market Indexes
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.